Cryolife Inc (CRY) Director Ronald D. Mccall Sells 3,700 Shares
Cryolife Inc (NYSE:CRY) Director Ronald D. Mccall sold 3,700 shares of the firm’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $28.74, for a total transaction of $106,338.00. Following the transaction, the director now directly owns 139,162 shares of the company’s stock, valued at $3,999,515.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
CRY opened at $28.33 on Friday. The firm has a market cap of $1.06 billion, a P/E ratio of 108.96 and a beta of 0.54. Cryolife Inc has a fifty-two week low of $23.99 and a fifty-two week high of $36.05. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.90 and a quick ratio of 3.69.
Cryolife (NYSE:CRY) last released its quarterly earnings data on Tuesday, April 30th. The medical equipment provider reported $0.04 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.04. Cryolife had a negative net margin of 0.09% and a positive return on equity of 3.79%. The business had revenue of $67.50 million during the quarter, compared to analyst estimates of $66.37 million. During the same quarter last year, the business earned $0.02 earnings per share. Cryolife’s quarterly revenue was up 9.0% compared to the same quarter last year. As a group, research analysts predict that Cryolife Inc will post 0.31 EPS for the current year.
Several equities analysts recently weighed in on the stock. TheStreet cut shares of Cryolife from a “b-” rating to a “c+” rating in a research note on Wednesday. ValuEngine cut shares of Cryolife from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cryolife in a research note on Sunday, May 12th. Canaccord Genuity reaffirmed a “buy” rating and set a $35.00 target price (up from $32.00) on shares of Cryolife in a research note on Wednesday, May 1st. Finally, Zacks Investment Research raised shares of Cryolife from a “sell” rating to a “hold” rating in a research note on Tuesday, April 23rd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Cryolife presently has a consensus rating of “Buy” and an average price target of $31.91.
Cryolife Company Profile
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.